164 related articles for article (PubMed ID: 21351319)
1. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
3. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl.
D'Andrea LD; Testa I; Panico M; Di Stasi R; Caracò C; Tarallo L; Arra C; Barbieri A; Romanelli A; Aloj L
Biopolymers; 2008; 90(5):707-12. PubMed ID: 18615495
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling approaches for cholecystokinin B receptor imaging.
Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
[TBL] [Abstract][Full Text] [Related]
9. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
10. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
Stone SR; Giragossian C; Mierke DF; Jackson GE
Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
[TBL] [Abstract][Full Text] [Related]
11. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
12. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
13. The [Tc(N)(PNP)]2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: in vitro and in vivo studies.
Agostini S; Bolzati C; Didonè E; Cavazza-Ceccato M; Refosco F; Aloj L; Arra C; Aurilio M; Tornesello AL; Tesauro D; Morelli G
J Pept Sci; 2007 Apr; 13(4):211-9. PubMed ID: 17269133
[TBL] [Abstract][Full Text] [Related]
14. Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.
Laverman P; Joosten L; Eek A; Roosenburg S; Peitl PK; Maina T; Mäcke H; Aloj L; von Guggenberg E; Sosabowski JK; de Jong M; Reubi JC; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1410-6. PubMed ID: 21461732
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.
Aloj L; Caracò C; Panico M; Zannetti A; Del Vecchio S; Tesauro D; De Luca S; Arra C; Pedone C; Morelli G; Salvatore M
J Nucl Med; 2004 Mar; 45(3):485-94. PubMed ID: 15001692
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
18. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.
Béhé M; Kluge G; Becker W; Gotthardt M; Behr TM
J Nucl Med; 2005 Jun; 46(6):1012-5. PubMed ID: 15937313
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging.
Aloj L; Panico M; Caraco C; Del Vecchio S; Arra C; Affuso A; Accardo A; Mansi R; Tesauro D; De Luca S; Pedone C; Visentin R; Mazzi U; Morelli G; Salvatore M
Cancer Biother Radiopharm; 2004 Feb; 19(1):93-8. PubMed ID: 15068617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]